Such effect was reverted using ADORA2b but not ADORA1 or ADORA2a antagonists, thus suggesting that only ADORA2b represents a promising therapeutic target for type 1 diabetes [68]. This evidence concerns the gene ADORA2B and type 1 diabetes mellitus.